Dr Tim Dreyer
Postdoctoral Research Associate
Department: Comparative Biomedical Sciences
Campus: Camden
Research Groups: Musculoskeletal Biology
Postdoctoral researcher in rare bone disease and drug repurposing, with a focus on sclerosteosis.
Timothy's research, under supervision of Dr Scott Roberts, aim to repurpose existing drugs to treat sclerosteosis, an ultra rare high bone mass skeletal disorder. His work involves developing, testing and refining experimental procedures to screen and test small molecules in relevant tissue culture systems. Promising drug candidates are then systematically assessed in preclinical models of skeletal disease.
Dreyer, T. J., Keen, J. a. C., Wells, L. M., Hopkinson, M., Orriss, I. R., Holdsworth, G., Pitsillides, A. A. & Roberts, S. J. 2025. Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies. Bone Research, 13, 44. (10.1038/s41413-025-00406-3)
Dreyer, T. J., Keen, J. a. C., Wells, L. M. & Roberts, S. J. 2023. Novel insights on the effect of sclerostin on bone and other organs. Journal of Endocrinology, 257, e220209. (10.1530/JOE-22-0209)
Dreyer, T., Shah, M., Doyle, C., Greenslade, K., Penney, M., Creeke, P., Kotian, A., Ke, H. Z., Naidoo, V. & Holdsworth, G. 2021. Recombinant sclerostin inhibits bone formation in vitro and in a mouse model of sclerosteosis. Journal of Orthopaedic Translation, 29, 134. (10.1016/j.jot.2021.05.005)
Dreyer, T., Nicholson, S., Ely, A., Arbuthnot, P. & Bloom, K. 2016. Improved antiviral efficacy using TALEN-mediated homology directed recombination to introduce artificial primary miRNAs into DNA of hepatitis B virus. Biochemical and Biophysical Research Communications, 478, 1563–1568. (https://doi.org/10.1016/j.bbrc.2016.08.152)